RedHill Biopharma (RDHL) Net Margin (2012 - 2023)

RedHill Biopharma (RDHL) has 12 years of Net Margin data on file, last reported at 3280.68% in Q2 2023.

• On a quarterly basis, Net Margin rose 328068.0% year-over-year to 3280.68% in Q2 2023; TTM through Jun 2023 was 142.68%, a 14268.0% increase from a year earlier, with the FY2025 full-year figure at 2675.17%, up 277797.0% from the prior year.
• Net Margin for Q2 2023 stood at 3280.68%, up from 220.03% in the prior quarter.
• Over the last five years, Net Margin for RDHL reached as high as 3280.68% in Q2 2023 and fell as low as 220.03% in Q1 2023.
• Historically, Net Margin has averaged 180.04% across 5 years, with a median of 0.0% in 2021.
• On a YoY basis, Net Margin climbed as much as 328068 bps in 2023 and fell as far as 22003 bps in 2023.
• Year by year, Net Margin stood at 0.0% in 2019, then plunged by 83 bps to 0.0% in 2020, then slumped by 31 bps to 0.0% in 2021, then jumped by 51 bps to 0.0% in 2022, then soared by 2000000000 bps to 3280.68% in 2023.
• Per Business Quant data, the three most recent Net Margin figures were 3280.68% in Q2 2023, 220.03% in Q1 2023, and 0.0% in Q3 2022.